Table 3 Management and prognosis of KFD patients
From: Macrophage activation syndrome in children with Kikuchi-Fujimoto disease
Without MAS (n = 43) | With MAS (n = 15) | p-value | |
|---|---|---|---|
Treatment | |||
IVIG | 7 (16.3%) | 3(20.0%) | > 0.9999 |
Glucocorticoids | 15 (34.9%) | 12 (80.0%) | 0.003 |
Cyclosporine | 0 (0.0%) | 1 (6.7%) | 0.26 |
VP-16 | 0 (0.0%) | 1 (6.7%) | 0.26 |
Tofacitinib | 0 (0.0%) | 1 (6.7%) | 0.26 |
Antibiotics | 19 (66.7%) | 10 (66.7%) | 0.23 |
Hosptial durations (days) | 11 (9–13) | 11 (10–21) | 0.41 |
Recurrence of KFD | 4 (9.3%) | 5 (33.3%) | 0.04 |
Progression to autoimmune diseases | 2 (4.7%) | 1 (6.7%) | > 0.9999 |